“…Chemotherapy induced leucopenia (CIL) is a common and significant adverse effect of chemotherapy, defined as a leucopenia count of <4.00×10 9 /L, and it can put patients at risk for severe infection (Lyman et al, 2010;Lyman and Kleiner, 2011). It is also the major dose-limiting toxicity, and it is frequently managed by reducing or delaying the chemotherapy (Delbaldo et al, 2004;Hangaishi, 2011;Saloustros et al, 2011), which can result in lower diseasefree and overall survival (Kvinnsland et al, 1999;Gurney Schiller et al, 2002;Pfister et al, 2004), However, research (Shitara et al, 2011) on breast cancer (Saarto et al, 1997;Poikonen et al, 1999;Cameron et al, 2003;Shitara et al, 2010;Han et al, 2012), small-cell lung cancer (Banerji et al, 2006), osteosarcoma (Ratain, 1998), ovarian cancer (Sawyer and Ratain., 2001) have shown the association between chemotherapy-induced neutropenia and better clinical outcome for patients. It is not associated with increased risk for death (Souza-Dantas et al, 2011).…”